Table 2.
ROC analysis of CSF parameters for DLB versus AD
| CSF variables | Number of patients* | Youden index¶ | Associated criterion§ | Sensitivity (%) | Specificity (%) | AUC (95% CI) |
|---|---|---|---|---|---|---|
| DLB-(pro+d) vs AD-(pro+d) | ||||||
| t-α-synuclein | 0.484 | > 139 ng/L | 72.3 | 76.1 | 0.78 (0.70 to 0.85) | |
| t-Tau |
DLB n = 67 AD n = 65 |
0.713 | > 371 ng/L | 89.2 | 82.1 | 0.92 (0.86 to 0.96) |
| Phospho-Tau181 | 0.773 | > 58 ng/L | 90.8 | 86.6 | 0.93 (0.87 to 0.97) | |
| Aβ42 | 0.490 | ≤ 838 ng/L | 90.8 | 58.2 | 0.77 (0.69 to 0.84) | |
| t-Tau_phospho-Tau_Aβ42¥ | 0.787 | > 0.4714 | 87.7 | 91.0 | 0.95 (0.89 to 0.98) | |
| t-Tau_phospho-Tau_Aβ42_t-α-syn¥ | 0.802 | > 0.516 | 86.2 | 94.0 | 0.95 (0.90 to 0.98) | |
| Aβ40 |
DLB n = 34 AD n = 25 |
0.474 | > 9563 | 68.0 | 79.4 | 0.70 (0.57 to 0.81) |
| Aβ42/Aβ40 | 0.731 | ≤ 0.0555 | 76.0 | 97.1 | 0.93 (0.83 to 0.98) | |
| t-Tau_phospho-Tau_Aβ42/Aβ40¥ | 0.840 | > 0.5368 | 84.0 | 100 | 0.95 (0.86 to 0.99) | |
| t-Tau_phospho-Tau_Aβ42/Aβ40_t-α-syn¥ | 0.840 | > 0.5442 | 84.0 | 100 | 0.95 (0.86 to 0.99) | |
| Pro-DLB vs Pro-AD | ||||||
| t-α-synuclein | 0.583 | > 139 ng/L | 81.8 | 76.5 | 0.83 (0.73 to 0.90) | |
| t-Tau |
DLB n = 51 AD n = 33 |
0.701 | > 371 ng/L | 81.8 | 88.2 | 0.89 (0.81 to 0.95) |
| Phospho-Tau181 | 0.800 | > 60 ng/L | 87.9 | 92.2 | 0.92 (0.84 to 0.97) | |
| Aβ42 | 0.476 | ≤ 838 ng/L | 84.9 | 62.8 | 0.75 (0.64 to 0.84) | |
| t-Tau_phospho-Tau_Aβ42¥ | 0.779 | > 0.498 | 81.8 | 96.1 | 0.93 (0.86 to 0.98) | |
| t-Tau_phospho-Tau_Aβ42_t-α-syn¥ | 0.770 | > 0.480 | 84.9 | 92.2 | 0.95 (0.88 to 0.98) | |
| Aβ40 | 0.536 | > 9563 | 75.0 | 78.6 | 0.75 (0.60 to 0.87) | |
| Aβ42/Aβ40 | 0.777 | ≤ 0.0529 | 81.3 | 96.4 | 0.94 (0.82 to 0.99) | |
| t-Tau_phospho-Tau_Aβ42/Aβ40¥ |
DLB n = 28 AD n = 16 |
0.875 | > 0.5111 | 87.5 | 100 | 0.95 (0.84 to 0.99) |
| t-Tau_phospho-Tau_Aβ42/Aβ40_t-α-syn¥ | 0.875 | > 0.5148 | 87.5 | 100 | 0.95 (0.83 to 0.99) | |
| DLB-d vs AD-d | ||||||
| t-α-synuclein | 0.469 | > 92.275 ng/L | 90.6 | 56.3 | 0.75 (0.60 to 0.86) | |
| t-Tau |
DLB n = 16 AD n = 32 |
0.750 | > 441 ng/L | 81.3 | 93.8 | 0.94 (0.83 to 0.99) |
| phospho-Tau181 | 0.750 | > 56 ng/L | 93.8 | 81.3 | 0.93 (0.82 to 0.99) | |
| Aβ42 | 0.406 | ≤ 781 ng/L | 96.9 | 43.8 | 0.73 (0.58 to 0.85) | |
| t-Tau_phospho-Tau_Aβ42¥ | 0.813 | > 0.6032 | 81.3 | 100 | 0.96 (0.86 to 1.00) | |
| t-Tau_phospho-Tau_Aβ42_t-α-syn¥ | 0.781 | > 0.4877 | 96.9 | 81.3 | 0.96 (0.86 to 1.00) | |
| Aβ40 |
DLB n = 6 AD n = 9 |
0.389 | > 9183 | 55.6 | 83.3 | 0.65 (0.37 to 0.87) |
| Aβ42/Aβ40 | 0.667 | ≤ 0.056 | 66.7 | 100 | 0.91 (0.65 to 0.99) | |
| t-Tau_phospho-Tau_Aβ42/Aβ40¥ | 0.778 | > 0.5201 | 77.8 | 100 | 0.93 (0.67 to 1.00) | |
| t-Tau_phospho-Tau_Aβ42/Aβ40 t-α-syn¥ | 0.889 | > 0.5354 | 88.9 | 100 | 0.96 (0.72 to 1.00) | |
*Due to missing CSF, some patients could not have an Aβ40 assay
¶Youden index: sensitivity + specificity – 1
§Cut-off associated with the Youden index
¥Consideration of three or four parameters with a multiple regression